Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dense Breasts Clear all
Not listed No phase listed Observational Accepts healthy volunteers

OctavaPink for Women With Dense Breast After Negative Mammography

NCT02209389
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI
Device
Lead sponsor
Eventus Diagnostics Ltd
Industry
Eligibility
30 Years to 79 Years · Female only
Enrollment
1,750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Jun 26, 2026, 6:27 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Precision Supplemental Imaging in Women With Dense Breasts

NCT07277738
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
Prognosia Breast, Mammogram, MRI
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00270894
View directory record Official record
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Not applicable Interventional

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

NCT00617370
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma of the Breast
Interventions
epirubicin, cyclophosphamide, Paclitaxel,
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

NCT02489448
View directory record Official record
Conditions
Breast Neoplasms
Interventions
MEDI4736
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Jun 26, 2026, 6:27 AM EDT
Completed No phase listed Observational

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

NCT00897026
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, paclitaxel, fluorescence in situ hybridization, immunohistochemistry staining method
Drug · Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

NCT00944047
View directory record Official record
Conditions
Breast Cancer
Interventions
nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
Drug · Biological · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Hays, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer

NCT00201708
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Doxorubicin, Cyclophosphamide (AC)
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Jun 26, 2026, 6:27 AM EDT
Completed No phase listed Observational

Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging

NCT01027767
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 26, 2026, 6:27 AM EDT
Not listed Phase 2 Interventional

Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study

NCT00378638
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab combined with dose dense chemotherapy
Drug
Lead sponsor
Chap, Linnea I., M.D.
Individual
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2007 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

NCT00232479
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel and carboplatin in dose dense regimen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Jun 26, 2026, 6:27 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

NCT03329378
View directory record Official record
Conditions
Locally Advanced Breast Cancer
Interventions
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jun 26, 2026, 6:27 AM EDT
Not listed Phase 2 Interventional

Capecitabine in Metastatic Breast and GI Cancers

NCT02595320
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer
Interventions
Capecitabine
Drug
Lead sponsor
Qamar Khan
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
15
States / cities
Fairway, Kansas • Garden City, Kansas • Great Bend, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2021 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00003953
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, docetaxel, doxorubicin hydrochloride, tamoxifen citrate, autologous bone marrow transplantation, surgical procedure, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00470301
View directory record Official record
Conditions
Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
tipifarnib, paclitaxel, doxorubicin, cyclophosphamide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Tampa, Florida • New York, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jun 26, 2026, 6:27 AM EDT
Terminated Phase 1Phase 2 Interventional

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

NCT01697293
View directory record Official record
Conditions
Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Therapeutic Conventional Surgery, Triciribine Phosphate
Drug · Other · Procedure
Lead sponsor
Prescient Therapeutics, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Tampa, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue

NCT03220893
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Digital Breast Tomosynthesis (DBT), Scintimammography
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
3,023 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
5
States / cities
Detroit, Michigan • Rochester, Minnesota • Toledo, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jun 26, 2026, 6:27 AM EDT
Completed No phase listed Observational

Delphinus SoftVue Prospective Case Collection - ARM 2

NCT02977247
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Non-Interventional, Automated Whole Breast Ultrasound
Other · Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Miami Beach, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 26, 2026, 6:27 AM EDT
Active, not recruiting Phase 2 Interventional

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 26, 2026, 6:27 AM EDT
Recruiting No phase listed Observational

ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)

NCT07505797
View directory record Official record
Conditions
Breast Cancer, Benign Breast Condition, Breast Fibroadenoma, Breast Neoplasms, Breast Disease, Breast Cancer Female, Breast Pain, Breast Cancer Invasive
Interventions
ATUSA 3D Automated Breast Ultrasound System
Device
Lead sponsor
iSono Health, Inc.
Industry
Eligibility
18 Years to 94 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 26, 2026, 6:27 AM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jun 26, 2026, 6:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Histology of Functional Density in Premenopausal Breast

NCT01588834
View directory record Official record
Conditions
Dense Breasts, Breast Cancer
Interventions
breast biopsy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Jun 26, 2026, 6:27 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up

NCT01723124
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Jun 26, 2026, 6:27 AM EDT